VITAL THERAPIES, INC. (NASDAQ:VTL) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
(the Annual Meeting). Of the 40,894,876 shares of our common
stock outstanding as of the record date of March 29, 2017,
33,963,019 shares were represented at the Annual Meeting, either
in person or by proxy, constituting approximately 83.05% of the
outstanding shares of common stock. The matters voted on at the
Annual Meeting and the votes cast with respect to each such
matter are set forth below:
|
1.
|
Election of Class III Directors. Each of the following
nominees was elected to serve as a Class III director, to hold office until our 2020 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified based on the following results of voting: |
|
Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|||
|
Cheryl L. Cohen
|
20,294,286
|
2,308,875
|
11,359,858
|
|||
|
Errol R. Halperin
|
19,980,860
|
2,622,301
|
11,359,858
|
|||
|
J. Michael Millis, M.D.
|
18,701,157
|
3,902,004
|
11,359,858
|
|||
|
Lowell E. Sears
|
20,295,029
|
2,308,132
|
11,359,858
|
|
2.
|
Ratification of Appointment of Independent Registered
Public Accounting Firm. The appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017 was ratified based on the following results of the voting: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||
|
33,858,775
|
99,039
|
5,205
|
About VITAL THERAPIES, INC.> (NASDAQ:VTL)
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges. VITAL THERAPIES, INC.> (NASDAQ:VTL) Recent Trading Information
VITAL THERAPIES, INC.> (NASDAQ:VTL) closed its last trading session 00.00 at 3.20 with 131,502 shares trading hands.